| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A comparison between genetically humanized and chimeric liver humanized mouse models for studies in drug metabolism and toxicity
|
Scheer, Nico
|
|
2016
|
21 |
2 |
p. 250-263
14 p.
|
article
|
| 2 |
An analysis of FDA-approved drugs: natural products and their derivatives
|
Patridge, Eric
|
|
2016
|
21 |
2 |
p. 204-207
4 p.
|
article
|
| 3 |
Bridging the translational gap: collaborative drug development and dispelling the stigma of commercialization
|
Yu, Helen W.H.
|
|
2016
|
21 |
2 |
p. 299-305
7 p.
|
article
|
| 4 |
Conformational stability and self-association equilibrium in biologics
|
Clarkson, Benjamin R.
|
|
2016
|
21 |
2 |
p. 342-347
6 p.
|
article
|
| 5 |
Contents page 2
|
|
|
2016
|
21 |
2 |
p. ii-
1 p.
|
article
|
| 6 |
Contents page 1
|
|
|
2016
|
21 |
2 |
p. i-
1 p.
|
article
|
| 7 |
Cyclodextrins in pharmaceutical formulations II: solubilization, binding constant, and complexation efficiency
|
Jambhekar, Sunil S.
|
|
2016
|
21 |
2 |
p. 363-368
6 p.
|
article
|
| 8 |
Cyclodextrins in pharmaceutical formulations I: structure and physicochemical properties, formation of complexes, and types of complex
|
Jambhekar, Sunil S.
|
|
2016
|
21 |
2 |
p. 356-362
7 p.
|
article
|
| 9 |
Drug regulators and ethics: which GCP issues are also ethical issues?
|
Bernabe, Rosemarie D.L.C.
|
|
2016
|
21 |
2 |
p. 217-224
8 p.
|
article
|
| 10 |
Emerging therapeutic targets for the treatment of hepatic fibrosis
|
Fagone, Paolo
|
|
2016
|
21 |
2 |
p. 369-375
7 p.
|
article
|
| 11 |
Extensions of indication throughout the drug product lifecycle: a quantitative analysis
|
Langedijk, Joris
|
|
2016
|
21 |
2 |
p. 348-355
8 p.
|
article
|
| 12 |
Immunotoxin therapy for hematologic malignancies: where are we heading?
|
Madhumathi, Jayaprakasam
|
|
2016
|
21 |
2 |
p. 325-332
8 p.
|
article
|
| 13 |
In silico methods to address polypharmacology: current status, applications and future perspectives
|
Lavecchia, Antonio
|
|
2016
|
21 |
2 |
p. 288-298
11 p.
|
article
|
| 14 |
Key strategic factors for stakeholders in the current global biosimilar market
|
Casey, Daniel
|
|
2016
|
21 |
2 |
p. 208-211
4 p.
|
article
|
| 15 |
Kynurenine-3-monooxygenase: a review of structure, mechanism, and inhibitors
|
Smith, Jason R.
|
|
2016
|
21 |
2 |
p. 315-324
10 p.
|
article
|
| 16 |
Mapping lifecycle management activities for blockbuster drugs in Japan based on drug approvals and patent term extensions
|
Yamanaka, Takayuki
|
|
2016
|
21 |
2 |
p. 306-314
9 p.
|
article
|
| 17 |
Modelling of compound combination effects and applications to efficacy and toxicity: state-of-the-art, challenges and perspectives
|
Bulusu, Krishna C.
|
|
2016
|
21 |
2 |
p. 225-238
14 p.
|
article
|
| 18 |
Natural polyphenols: potential in the prevention of sexually transmitted viral infections
|
Date, Abhijit A.
|
|
2016
|
21 |
2 |
p. 333-341
9 p.
|
article
|
| 19 |
Proteomics and drug discovery in cancer
|
Dias, Matheus H.
|
|
2016
|
21 |
2 |
p. 264-277
14 p.
|
article
|
| 20 |
Repurposing historical control clinical trial data to provide safety context
|
Bhuyan, Prakash
|
|
2016
|
21 |
2 |
p. 212-216
5 p.
|
article
|
| 21 |
The prescription's prescription: enhanced pharmaceutical planning through use of a product health assessment
|
Ashkenazy, Rebecca
|
|
2016
|
21 |
2 |
p. 201-203
3 p.
|
article
|
| 22 |
The role of the 14-3-3 protein family in health, disease, and drug development
|
Aghazadeh, Yasaman
|
|
2016
|
21 |
2 |
p. 278-287
10 p.
|
article
|
| 23 |
Why and how have drug discovery strategies in pharma changed? What are the new mindsets?
|
Mignani, Serge
|
|
2016
|
21 |
2 |
p. 239-249
11 p.
|
article
|
Journal description